Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

NZ sharemarket up 0.4% after a2 Milk surge
Markets Market Close

NZ sharemarket up 0.4% after a2 Milk surge

The S&P/NZX 50 Index closed at 12,266.25, gaining 57.2 points or 0.47%.

Goldman Sachs downgrades Fletcher Building to sell
Markets

Goldman Sachs downgrades Fletcher Building to sell

Goldman Sach analysts have a 12-month target price of A$2.85 ($3.14).

Rayonier exits NZ with $1.2b forestry sale
Primary Sector

Rayonier exits NZ with $1.2b forestry sale

An investment firm bought the stake, which included 116,145 hectares of forestry.

NZME board told 'compromise or be rolled'
Markets

NZME board told 'compromise or be rolled'

Minority shareholders are falling in behind billionaire Jim Grenon's board coup.